retatrutide phase 2 trial dose escalation schedule Eli Lilly just announced striking 3 results for retatrutide, an experimental “triple agonist” that acts on three gut-hormone targets at once. On the top dose, people lost an average of 28% Eli Lilly's retatrutide shows promising

When you speed up the production of new blood cells with blood donation, it means your A1C is measuring the amount of glucose attached to younger cells

These devices allow patients to self-administer precise doses with minimal training, improving treatment adherence and convenience

Scale changes during this phase average two to four pounds for most patients

In its third and final clinical trial phase (including 3,127 adults), Eli Lilly's weight loss pill resulted in a 12.4% weight loss at 72 weeks for obese participants without type 2 diabetes who took the highest dose of the medication

Timeline: Experts expect it may take another 23 years before it becomes available